Unlocking Nucleic Acid Sensing Pathway Drug Targets - Ventus Therapeutics

contact ENG | FR

Unlocking Nucleic Acid Sensing Pathway Drug Targets with Kelly Pike, PhD, Head of Immunology and Scientific Affairs, Ventus Therapeutics and Thomas Tuschl, PhD, Professor of RNA Molecular Biology, The Rockefeller University

We are on the cusp of breaking through in an area that has really faced severe challenges.
- Kelly Pike, PhD
I'm very excited about the unique opportunity that Ventus is giving us in discovering and exploiting innate immunology pathways to make new drugs.
- Thomas Tuschl, PhD